

Aug 04, 2022

Sample Collection and Measurement of Serum Neurofilament Light (NfL)

Huw Morris^{1,2}, Donald Grosset³, Amanda Heslegrave⁴, Henrik Zetterberg⁵

¹Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK;

²Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, 20815;

³Glasgow University;

⁴Senior Research Fellow, UKDRI Fluid Biomarker Laboratory, UCL Queen Square Institute of Neurology, London, UK;

⁵UKDRI Fluid Biomarker Laboratory, UCL Queen Square Institute of Neurology, London, UK

1 Works for me

Share

dx.doi.org/10.17504/protocols.io.bzbep2je

h.morris

ABSTRACT

This protocol details the steps for the preparation of serum from human blood samples and the measurement of NfL concentration using the NF-Light Advantage kit on the HD-X Analyzer (Quanterix, Billerica, MA).

DOI

dx.doi.org/10.17504/protocols.io.bzbep2je

EXTERNAL LINK

<https://doi.org/10.1136/jnnp-2021-328365>

PROTOCOL CITATION

Huw Morris, Donald Grosset, Amanda Heslegrave, Henrik Zetterberg 2022. Sample Collection and Measurement of Serum Neurofilament Light (NfL). **protocols.io** <https://protocols.io/view/sample-collection-and-measurement-of-serum-neurofi-bzbep2je>



FUNDERS ACKNOWLEDGEMENT

Parkinson's UK

Grant ID: H-1703

The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Aligning Science Across Parkinson's (ASAP) initiative.

Grant ID: ASAP-000478

MANUSCRIPT CITATION please remember to cite the following publication along with this protocol

Vijiaratnam N, Lawton M, Heslegrave AJ, Guo T, Tan M, Jabbari E, Real R, Woodside J, Grosset K, Chelban V, Athauda D, Girges C, Barker RA, Hardy J, Wood N, Houlden H, Williams N, Ben-Shlomo Y, Zetterberg H, Grosset DG, Foltynie T, Morris HR, , Combining biomarkers for prognostic modelling of Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry 93(7). doi: [10.1136/jnnp-2021-328365](https://doi.org/10.1136/jnnp-2021-328365)

KEYWORDS

Parkinson's disease, Blood, Serum, Neurofilament Light (NfL), Prognostic Modelling Biomarkers, ASAPCRN

LICENSE

————— This is an open access protocol distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

CREATED

Oct 21, 2021

LAST MODIFIED

Aug 04, 2022

OWNERSHIP HISTORY

Oct 21, 2021  Oke Avwenagha

Oct 26, 2021  h.morris

PROTOCOL INTEGER ID

54342

MATERIALS TEXT

BD Vacutainer™ SST™ II Advance Tubes

<https://www.fishersci.co.uk/shop/products/vacutainer-sst-ii-advance-tubes/12927696>

Simoa® NF-light Advantage Kit

<https://www.quanterix.com/simoa-assay-kits/nf-light/>

HD-X Analyzer (Quanterix, Billerica, MA)

<https://www.quanterix.com/instruments/simoa-hd-x-analyzer/>

SAFETY WARNINGS

Venepuncture, the handling and transport of blood has the potential to expose research and clinical personnel, and other professionals to blood borne pathogens. Those performing a venepuncture, handling or disposing clinical waste must be trained, competent and adhere to local health & safety policies, risk assessments and standard operating procedures.

BEFORE STARTING

Check the planned procedure is covered by existing Research Ethics Committee approval and other required approvals.

Check that you have the correct personal protective equipment, supplies and consumables.

Blood Sample Collection and Serum Preparation

1h 10m

- 1 At enrolment, collect 10 mL of venous blood from each participant in Serum Separator Tubes^{30m} (SST): <https://www.fishersci.co.uk/shop/products/vacutainer-sst-ii-advance-tubes/12927696>



Venepuncture and the handling of blood has the potential to expose research and clinical personnel to blood borne pathogens. In order to minimise risk, personnel performing a venepuncture must have received appropriate training and deemed competent. Institutional health & safety policies, risk assessments and standard operating procedures must be followed.

2





15m

Within 1 hour of collection, centrifuge the SSTs at 2,500g for 15 minutes at room temperature

3

Print cryogenic labels / barcodes and apply to cryotubes: <https://www.brady.co.uk/labels>^{10m}

- 4 Aliquot approx.  **-0.5 mL** serum into labelled cryotubes, box and/or rack then store at ^{15m}
 **-80 °C** .

Measurement of Serum NfL Concentration

- 5 Measure serum NfL concentration using the Simoa® NF-light Advantage Kit for HD-1 / HD-X following the manufacturers instructions : <https://www.quanterix.com/wp-content/uploads/2020/12/NF-light-Data-Sheet-HD-1%E2%88%95HD-X-2.pdf>

This kit is a digital immunoassay for the quantitative determination of NfL in serum, plasma and CSF.

***The measurement of serum NfL concentration is performed blinded to clinical diagnosis.**

- 6 Run on the HD-X Analyzer (Quanterix, Billerica, MA), a fully automated Simoa® bead-based immunoassay platform: <https://www.quanterix.com/instruments/simoa-hd-x-analyzer/>

Key References

Gisslén M, Price RW, Andreasson U, *et al*. Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. EBioMedicine 2016;3:135–40. doi:[10.1016/j.ebiom.2015.11.036](https://doi.org/10.1016/j.ebiom.2015.11.036)